Rnaz stock forecast.
TransCode common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on Tuesday, May 23, 2023, under the current trading symbol, “RNAZ.”
Dec 4, 2023 · The RNAZ stock price is -10536.36% off its 52-week high price of $23.40 and 31.82% above the 52-week low of $0.15. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.59 million shares traded. The 3-month trading volume is 6.95 million shares. The consensus among analysts is that TransCode Therapeutics ... Stock Price Forecast The 1 analysts offering 12-month price forecasts for Transcode Therapeutics Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00. Is RNAZ stock a Buy, Hold, or Sell, according to Wall Street analysts? ... You can dig deeper into what analysts are projecting on the Transcode Therapeutics stock forecast page. RNAZ Technical Indicators. SMA10 10.32. SMA20 10.31. SMA50 10.3. SMA100 10.24. SMA200 10.2. MACD 0.01. MACD Signal 0.01.Nov 1, 2021 · Novavax (NVAX) stock forecast: Targets for 2022, 2025 and 2027. Algorithm-based NVAX stock forecast from Wallet Investor (as of 20 January) estimated the price to reach $189.77 by the end of 2022, $268.69 by the end of 2023 and to hit $435.51 by the end of 2025. Although the service did not provide targets for 2030, its 5-year Novevax share ... According to analyst projections, RNAZ’s forecast low is $3.00 with $3.00 as the target high. To hit the forecast high, the stock’s price needs a -1263.64% plunge from its current level, while the stock would need to soar -1263.64% for it to hit the projected low. TransCode Therapeutics Inc (RNAZ) estimates and forecasts
Sell candidate since Nov 16, 2023 Loss -7.64% PDF. The Salarius Pharmaceuticals Inc. stock price fell by -4.58% on the last day (Wednesday, 22nd Nov 2023) from $0.668 to $0.637. It has now fallen 6 days in a row. During the last trading day the stock fluctuated 8.78% from a day low at $0.625 to a day high of $0.680.
If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.
5.17. -5.14%. 31.52M. Find the latest Transcode Therapeutics Inc (RNAZ) stock forecast, 12-month price target, predictions and analyst recommendations.TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) – Analysts at HC Wainwright reduced their FY2023 EPS estimates for TransCode Therapeutics in a research note issued to investors on Wednesday, November 15th.HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($5.57) per share for the …Get the latest TransCode Therapeutics, Inc. (RNAZ) stock news and headlines to help you in your trading and investing decisions. Research TransCode Therapeutics' (Nasdaq:RNAZ) stock key valuation metrics while comparing it with its industry peers & market side by side. Research TransCode ... This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors. RNAZ PB Ratio vs Fair Ratio. Fair Ratio; Current ...RNAZ stock forecast . Since RNAZ is a newly listed company with a market cap of only about $50 million, none of the analysts are covering the stock. The forecast for RNAZ will eventually depend on ...
Stock analysis for TransCode Therapeutics Inc (RNAZ:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
What this means: InvestorsObserver gives Transcode Therapeutics Inc (RNAZ) an overall rank of 30, which is below average. Transcode Therapeutics Inc is in the bottom half of …
Each share of common stock (or Pre-Funded Warrant) is being sold at a public offering price of $0.51 per share (inclusive of the Pre-Funded Warrant exercise price of $0.01).Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET.Forecast Changes; Commodities. Gold; Copper; Crude Oil; ... TransCode Therapeutics, Inc. Common Stock (RNAZ) Nasdaq Listed; Nasdaq 100; ... RNAZ RNAZ AFTER HOURS QUOTE RNAZ LATEST AFTER HOURS TRADES.Sep 25, 2023 · The 1 analyst offering 12-month price forecasts for RNAZ had a median target of $12.00, with both the high and low estimates also at $12.00. This median estimate represents a staggering +1,675.94% increase from the last reported price of $0.68. The consensus among 1 polled investment analyst is to buy stock in Transcode Therapeutics Inc. Discover historical prices for RNAZ stock on Yahoo Finance. View daily, weekly or monthly format back to when TransCode Therapeutics, Inc. stock was issued.
About the TransCode Therapeutics, Inc. Common Stock stock forecast. As of 2023 November 27, Monday current price of RNAZ stock is 0.240$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Transcode Therapeutics stock price has been showing a declining tendency so we …Dec 4, 2023 · The RNAZ stock price is -10536.36% off its 52-week high price of $23.40 and 31.82% above the 52-week low of $0.15. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.59 million shares traded. The 3-month trading volume is 6.95 million shares. The consensus among analysts is that TransCode Therapeutics ... While only two analysts cover RNAZ stock according to TipRanks, they are incredibly bullish on its prospects. Both experts forecast shares hitting $12 , translating to over 400% upside, even with ...Earnings for TransCode Therapeutics are expected to grow in the coming year, from ($5.57) to ($0.63) per share. TransCode Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 29th, 2024 based off prior year's report dates. Read More.Stock Price Forecast. The 2 analysts offering 12-month price forecasts for Vistagen Therapeutics Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00.According to . 1 Wall Street analyst that have issued a 1 year RNAZ price target, the average RNAZ price target is $3.00, with the highest RNAZ stock price forecast at $3.00 and the lowest RNAZ stock price forecast at $3.00. According to . 1 Wall Street analyst that have issued a 1 year RNAZ price target, the average RNAZ price target is $3.00, with the highest RNAZ stock price forecast at $3.00 and the lowest RNAZ stock price forecast at $3.00.
Should I buy Transcode Therapeutics (RNAZ)? Use the Zacks Rank and Style Scores to find out is RNAZ is right for your portfolio.TransCode Therapeutics, Inc. Common Stock (RNAZ) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.
Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Salarius Pharmaceuticals Inc have a median target of 3.25, with a high estimate of 3.25 and a low estimate of 3.25. The ... Their RNAZ share price targets range from $12.00 to $12.00. On average, they predict the company's share price to reach $12.00 in the next year. This suggests a …TSLA. Tesla, Inc. Common Stock. $230.05 +0.01. BETR. Better Home & Finance Holding Company Class A Common Stock. $1.56 +0.41 +35.65%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and ... Nasdaq +78.81(+0.55%) Russell 2000 1,862.64 +53.62(+2.96%) Crude Oil 74.38 -1.58(-2.08%) Gold 2,091.70 +34.50(+1.68%) TransCode Therapeutics, Inc. (RNAZ) NasdaqCM - NasdaqCM Real Time Price....High growth companies in the Pharmaceuticals-biotech industry. View Past Performance. Discover TransCode Therapeutics' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers.Nov 29, 2023 · TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including ... TransCode Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RNAZ updated stock price target summary.High growth companies in the Pharmaceuticals-biotech industry. View Past Performance. Discover TransCode Therapeutics' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers.
Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Salarius Pharmaceuticals Inc have a median target of 3.25, with a high estimate of 3.25 and a low estimate of 3.25. The ...
RNAZ: TransCode Therapeutics broker recommendation chart. Get the latest chart with broker recommendations from Zacks Investment Research.
You may want to consider selling the stock, shorting the stock, or exploring put options on RNAZ as a result. In of 42 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are . The Aroon Indicator for RNAZ entered a downward trend on November 24, 2023.Using The Trader's Cheat Sheet To Identify Support & Resistance: Watch the Webinar. Projection Effective Date: Oct 23rd, 2023. Legend: Blue areas below the Last Price will tend to provide support to limit the downward move. Red areas above the Last Price will tend to provide resistance to limit the upward move.Stock Price Forecast. The 2 analysts offering 12-month price forecasts for Vistagen Therapeutics Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00. The ... Analyst Forecast. According to one analyst, the rating for RNAZ stock is "Strong Buy" and the 12-month stock price forecast is $3.0.RNAZ intends to sell 2.78 million shares of common stock at a midpoint price of $9.00 per share for gross proceeds of approximately $25 million, not including the sale of customary underwriter ...The average twelve-month price prediction for TransCode Therapeutics is $12.00 with a high price target of $12.00 and a low price target of $12.00. Learn more on RNAZ's analyst rating history. Do Wall Street analysts like TransCode Therapeutics more than its competitors? TransCode Therapeutics, Inc. Common Stock (RNAZ) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.View live TransCode Therapeutics, Inc. chart to track its stock's price action. Find market predictions, RNAZ financials and market news.Heading out for an outdoor adventure? Whether you’re planning a picnic, a hiking trip, or a beach day, one essential tool you need in your arsenal is a detailed weather 10 day forecast.
The 1 analyst offering 1 year price forecasts for RNAZ have a max estimate of — and a min estimate of —. Analyst rating Based on 1 analyst giving stock ratings to RNAZ in the past 3 months.View Past Performance. Discover TransCode Therapeutics' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing …RNAZ : 0.2620 (+0.77%) Positive Results Causes Pop In Biotech Stock Yolowire - Wed Oct 26, 2022. A Boston-based %Biotech company really captured the attention of traders on Wednesday after the it reported Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma.... RNAZ: TransCode Therapeutics broker recommendation chart. Get the latest chart with broker recommendations from Zacks Investment Research.Instagram:https://instagram. how much is 1776 to 1976 quarter dollar worthaphlf stock forecastu.s steel stocketf home builders Stock analysis for TransCode Therapeutics Inc (RNAZ:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. will tesla stock go up mondayicln ticker 3 ថ្ងៃមុន ... $0.22. RNAZ 10.98%. Mullen Automotive Inc. $0.16. MULN 7.57%. Citius Pharmaceuticals Inc. $0.77. CTXR 0.27%. micromobility.com inc. $0.013. MCOM ...Nov 1, 2021 · Novavax (NVAX) stock forecast: Targets for 2022, 2025 and 2027. Algorithm-based NVAX stock forecast from Wallet Investor (as of 20 January) estimated the price to reach $189.77 by the end of 2022, $268.69 by the end of 2023 and to hit $435.51 by the end of 2025. Although the service did not provide targets for 2030, its 5-year Novevax share ... tulip bulb bubble BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it is withdrawing the underwritten public offering of its common stock. This reflects the Company’s belief that current ...Nov 22, 2023 · Summit Therapeutics Inc. (NASDAQ:SMMT) issued its earnings results on Monday, November, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.09. The firm earned $6.12 million during the quarter.